EGFR在胰腺癌组织芯片中的表达及其临床意义的研究

Expression of EGFR in pancreatic carcinoma

目的:探讨表皮生长因子受体EGFR蛋白在胰腺癌组织中的表达及其与胰腺癌临床病理参数和生物学预后的相关性及意义。方法:将88例无术前放化疗史的胰腺癌手术标本和11例非肿瘤性胰腺组织制成组织芯片,采用免疫组化法检测EGFR蛋白的表达情况,并对随访2个月～6年的54例病例作生存分析。结果:获得1个胰腺癌组织芯片蜡块,含99个位点。EGFR在胰腺癌中的阳性表达率为59.1%(52/88),而11例非肿瘤性胰腺组织中均无EGFR的过度表达(0/11),两者比较差异有统计学意义(P<0.01),且EGFR表达与肿瘤大小及TNM分期相关(P<0.05)。单因素及多因素Cox生存分析显示,EGFR表达与胰腺癌患者预后相关,具有独立的预后意义(P<0.05)。结论:EGFR蛋白表达与胰腺癌临床病理参数及预后密切相关,可能作为胰腺癌的独立预后指标。

Objective： To investigate the expression of EGFR in pancreatic adenocarcinoma,and to explore its relationship with clinicopathologic parameters and the effect on prognosis.Methods： Immunohistochemical method was used to examine the expression of EGFR protein in tissues from 88 cases of pancreatic carcinoma without history of chemo-radiation therapy and from 11 cases without tumor.All 54 cases were followed-up from 2 months to 6 years.Results： A paraffin-embedded pancreatic carcinoma tissue microarray was successfully constructed,including 99 tissue spots.Positive expression rate of EGFR in tumors was 59.1%（52/88）.In contrast,no overexpression of EGFR in non tumorous pancreatic tissues was detected（P〈0.01）.The expression of EGFR was significantly correlated with size of tumor and TNM stage（P〈0.05）.Cox stepwise proportional hazards analysis showed that EGFR expression was associated with prognosis of pancreatic adenocarcinoma.Conclusions： The expression of EGFR is associated with clinicopathologic parameters and prognosis of pancreatic carcinoma.It would become a independent index for tumor prognosis.